Targets › PLN
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.
Reversibly inhibits the activity of ATP2A2/SERCA2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+). Binds preferentially to the ATP-bound E1 conformational form of ATP2A2 which predominates at low Ca(2+) concentrations during the diastolic phase of the cardiac cycle (By similarity). (UniProt, P26678)
Open in Phaseline: the race on PLN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | AZD4063 Phospholamban (PLN) inhibitor targeting R14del mutation | PLN | Phase 1 | Dilated Cardiomyopathy | Nov 2027 |
Dilated Cardiomyopathy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.